期刊
PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE
卷 23, 期 1, 页码 42-45出版社
WILEY
DOI: 10.1111/j.1600-0781.2007.00273.x
关键词
epidermal growth factor receptor inhibitor; erlotinib; photosensitivity; rash
类别
A papulopustular rash occurs in 45-100% of patients undergoing anti-cancer treatment with epidermal growth factor (EGFR) inhibitors. Although the majority of cases involve the face and upper trunk, ultraviolet radiation has not yet been documented to play a major role in inducing or exacerbating symptoms. We describe a 75-year-old man who was being treated with the EGFR inhibitor erlotinib and developed the characteristic rash on unprotected areas of the trunk after photoexposure, while the protected areas (face and neck) remained uninvolved. This case underscores the importance of sun protection in patients treated with EGFR inhibitors and supports in vitro data showing that EGFR blockade results in altered keratinocyte survival and proliferation in response to ultraviolet radiation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据